Zepbound vs Wegovy (injectable)

Before May 2025, the Zepbound vs Wegovy comparison was indirect — you'd compare SURMOUNT-1 to STEP-1, acknowledge the populations differed, and hedge. Then Lilly published SURMOUNT-5, a 72-week randomized head-to-head of tirzepatide 10 or 15 mg against semaglutide 2.4 mg in 751 adults with obesity without diabetes.

The result: tirzepatide produced 20.2% mean weight reduction versus 13.7% for semaglutide — a 47% relative advantage, highly statistically significant. Tirzepatide patients were also nearly 3x more likely to achieve ≥25% weight loss.

This is the single most important data point for patients choosing between these two drugs, and it confirmed what observational and cross-trial analyses had suggested. For most patients focused on weight loss, the efficacy answer is now unambiguous.

The SELECT trial (NEJM, 2023) followed 17,604 adults with obesity and established cardiovascular disease (but no diabetes) for an average of 40 months on semaglutide 2.4 mg versus placebo. The primary endpoint — a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke — occurred 20% less often on drug.

This is a landmark result and the reason Wegovy carries an FDA indication for cardiovascular risk reduction in adults with obesity and established CVD — an indication Zepbound does not have. Lilly is running SURMOUNT-MMO, an analogous trial for tirzepatide; results are expected 2027.

For a patient with obesity and a history of heart attack, stroke, or stable angina, the SELECT evidence is often the deciding factor. It's also the reason some Wegovy prescriptions now get Medicare Part D coverage through the CV risk reduction pathway — a door closed to Zepbound.

Cash-pay via manufacturer direct channels:

• Zepbound via LillyDirect Self Pay: $349/month (single-dose vials, 2.5–10 mg).
• Wegovy via NovoCare Pharmacy: $499/month (all doses).

With commercial insurance:

• Both carry savings cards that typically bring covered patients to $0–$25/month.
• Coverage breadth varies widely by plan. Some PBMs prefer Wegovy (legacy Novo contracts); newer 2025–2026 formularies increasingly include Zepbound at preferred tier.

Medicare:

• Zepbound is essentially uncovered (Part D statute).
• Wegovy may be covered under the CV risk reduction indication for qualifying patients.

Verdict: Zepbound is about $150/month cheaper on cash, and usually equivalent with commercial insurance. Medicare patients with heart disease should look hard at Wegovy first.

Both drugs share the GLP-1 class profile: nausea, diarrhea, vomiting, constipation, abdominal pain. In cross-trial comparisons, tirzepatide typically shows slightly lower peak nausea rates than semaglutide at matched efficacy, possibly because the dual GIP/GLP-1 mechanism produces more efficient weight loss per unit of GI side effect.

That said, at maximum doses both drugs are substantially more GI-active than at starting doses, and the titration schedule matters more than the molecule for day-to-day tolerability. Patients who can't tolerate either often do well on a slower titration — staying at each dose step for 6 weeks instead of 4.

Real-world safety: semaglutide has been on market since 2017 across Ozempic/Rybelsus/Wegovy, while tirzepatide only launched in 2022 (Mounjaro) / 2023 (Zepbound). If you weight real-world surveillance heavily, semaglutide has a longer track record.

Switching Wegovy → Zepbound is a common move for patients who've plateaued below goal on semaglutide. Typical prescriber playbook: stop Wegovy at maintenance dose, start Zepbound at 2.5 mg the following week, titrate normally. No washout required. Most patients see additional 3–5% weight loss within 3–6 months of switching.

Switching Zepbound → Wegovy is less common but reasonable when insurance changes, GI tolerability at Zepbound 10–15 mg is poor, or the patient wants the SELECT evidence. Typical transition: Zepbound 7.5 or 10 mg → Wegovy 1.7 mg → 2.4 mg.

Pick Zepbound if: your primary goal is maximum weight loss, you're paying cash, or you've plateaued on Wegovy.

Pick Wegovy if: you have established cardiovascular disease, you're on Medicare Part D seeking coverage via the CV indication, or your insurance prefers it.

For most commercially insured patients without known heart disease, Zepbound is a modestly better first choice in 2026. For patients who qualify for the SELECT population, Wegovy is the evidence-aligned pick.

Not sure? Take the Sherpa Matcher — it factors in your goals, budget, and coverage specifics.